Screening High-Risk Groups and the General Population for SARS-CoV-2 Nucleic Acids in a Mobile Biosafety Laboratory.

SARS-CoV-2 bio-protection mobile biosafety laboratory nucleic acid real-time PCR

Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2021
Historique:
received: 02 06 2021
accepted: 09 07 2021
entrez: 6 9 2021
pubmed: 7 9 2021
medline: 9 9 2021
Statut: epublish

Résumé

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has challenged public health systems worldwide. Therefore, large-scale testing capacity is extremely important diagnosis and exclusion diagnosis. However, fixed laboratories are limited or far away from remote areas. Fortunately, MBS-Lab is characterized by high mobility and rapid on-site detection of SARS-CoV-2 nucleic acid. MBS-Lab was first used in northern Australia during a melioidosis outbreak in 1997. The MBS-Lab and a well-trained diagnostic team were dispatched to Dongchang District, Tonghua City, Jilin Province, China to assist the SARS-CoV-2 virus screening and diagnosis on January 17, 2021. Altogether, 93,952 oropharyngeal swabs samples were collected and tested among the high-risk groups and the general population in Dongchang District. Two single samples were identified as positive in the second turn screening. In the second turn screening, 3 mixed samples (10 in 1) were identified as positive; 10 mixed samples were identified as positive in the third turn screening. By resampling again, one and four cases were identified as positive, respectively. The positive cases were properly isolated and treated in hospital and avoided to visit family members, friends, colleagues and any other persons. Through this way of large-scale screening, human-human spread of SARS-CoV-2 can be effectively avoided. In addition, all staff members strictly executed multiple safety precautions and reduce exposure risks. In the end, none of the staffs was infected with SARS-CoV-2 virus or other pathogens. As an emergency facility for infectious disease control, the MBS-Lab satisfies the requirements of ports and other remote areas far from fixed laboratories and supplements the capabilities of fixed laboratories.

Identifiants

pubmed: 34485233
doi: 10.3389/fpubh.2021.708476
pmc: PMC8414879
doi:

Substances chimiques

Nucleic Acids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

708476

Informations de copyright

Copyright © 2021 Guo, Li, Song, Xu and Huang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Infect Genet Evol. 2020 Sep;83:104351
pubmed: 32387564
ACS Infect Dis. 2020 Sep 11;6(9):2319-2336
pubmed: 32786280
Lancet. 1998 Nov 14;352(9140):1600
pubmed: 9843113
Zoonoses Public Health. 2012 Sep;59 Suppl 2:151-7
pubmed: 22958259
Genomics. 2020 Nov;112(6):5204-5213
pubmed: 32966857
Afr J Lab Med. 2020 Aug 20;9(2):1041
pubmed: 32934915
Biomed Instrum Technol. 2013 Jul-Aug;47(4):333-8
pubmed: 23919793
PLoS Negl Trop Dis. 2017 May 15;11(5):e0005622
pubmed: 28505171
Am J Clin Pathol. 2020 Apr 15;153(5):567-570
pubmed: 32190890
J Infect Dis. 2016 Oct 15;214(suppl 3):S250-S257
pubmed: 27638946
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
Curr Protoc Cytom. 2020 Jun;93(1):e77
pubmed: 32502333
PLoS Negl Trop Dis. 2017 Jun 19;11(6):e0005665
pubmed: 28628619
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Biosaf Health. 2019 Sep;1(2):56-58
pubmed: 32501443
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Euro Surveill. 2020 Dec;25(50):
pubmed: 33334398

Auteurs

Zhimin Guo (Z)

Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China.

Lin Li (L)

Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China.

Yuanyuan Song (Y)

Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China.

Jiancheng Xu (J)

Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China.

Jing Huang (J)

Department of Clinical Laboratory, The First Hospital of Jilin University, Changchun, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH